• Dured Dardari, Louis Potier, Ariane Sultan, Maude Francois, Jocelyne M'Bemba, Benjamin Bouillet, Lucy Chaillous, Laurence Kessler, Aurelie Carlier, Abdulkader Jalek, Ayoub Sbaa, Laurent Orlando, Elise Bobony, Bruno Detournay, Hilmar Kjartansson, Ragna Bjorg Arsaelsdottir, Baldur Tumi Baldursson, and Guillaume Charpentier.
• Diabetic Foot Unit, Centre Hospitalier sud Francilien Corbeil Essonnes, 91100 Corbeil-Essonnes, France.
• Medicina (Kaunas). 2022 Dec 1; 58 (12).

BackgroundCell and/or tissue-based wound care products have slowly advanced in the treatment of non-healing ulcers, however, few studies have evaluated the effectiveness of these devices in the management of severe diabetic foot ulcers.MethodThis study (KereFish) is part of a multi-national, multi-centre, randomised, controlled clinical investigation (Odin) with patients suffering from deep diabetic wounds, allowing peripheral artery disease as evaluated by an ankle brachial index equal or higher than 0.6. The study has parallel treatment groups: Group 1 treatment with Kerecis® Omega3 Wound™ versus Group 2 treatment with standard of care. The primary objective is to test the hypothesis that a larger number of severe diabetic ulcers and amputation wounds, including those with moderate arterial disease, will heal in 16 weeks when treated with Kerecis® Omega3 Wound™ than with standard of care.ConclusionThis study has received the ethics committee approval of each participating country. Inclusion of participants began in March 2020 and ended in July 2022. The first results will be presented in March 2023. The study is registered in ClinicalTrials.gov as Identifier: NCT04537520.

8 keywords...

hide…